Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
CREATE Medicines has successfully raised $122 million in a Series B financing round led by Newpath Partners and ARCH Venture Partners to advance its CAR-T therapy pipeline.
PRIVATEMay 14, 2026•3 months ago
Amount Raised
$122 Million
Round Type
Series B
CambridgeBiotechnologyHealth CareTherapeuticsInvestors
Alexandria Venture InvestmentsHatteras Venture PartnersArch Venture PartnersNewpath Partners
Description
CREATE Medicines, Inc. has announced the closure of its $122 million Series B funding round, co-led by Newpath Partners and ARCH Venture Partners. The funding will be used to support the advancement of its CAR-T therapy for autoimmune diseases and oncology. CREATE has already dosed over 50 patients in its clinical programs
Related People
Suggested for you
1 contactVerified contactsNo contacts on file at CREATE Medicines yet.
Funding Insights
Based on industry dataTimeline to next round
Series B companies typically work for 15-20 months before raising new capital
Growth expectations
Series B companies are expected to scale rapidly and expand market reach
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech